Physician profile
Jonathan M Erlich
NPI 1265796429
$13,169.98
in general payments reported to CMS, 2019-2025
39 companies · $5,617 in 2025
The $5,617 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $414 · 2021: $1,000 · 2022: $1,344 · 2023: $2,060 · 2024: $2,450 · 2025: $5,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,819 · Consulting Fee: $3,083 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,818.62 |
| Consulting Fee | $3,083.33 |
| Education | $226.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $3,083.33 | 2025 | Capsocam Colon |
| Janssen Biotech, INC. | $1,795.52 | 2020-2025 | Stelara, Tremfya |
| Abbvie INC. | $1,760.94 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,296.11 | 2020-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,005.91 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Medtronic, INC. | $428.12 | 2023-2024 | Gi Genius, Interstim, Barrx |
| Pfizer INC. | $409.90 | 2022-2025 | |
| Neuraxis, INC. | $386.36 | 2025 | |
| Endogastric Solutions, INC | $373.25 | 2021-2023 | Esophyx |
| Madrigal Pharmaceuticals | $284.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $214.53 | 2023-2025 | |
| Lilly USA, LLC | $189.86 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $185.11 | 2019-2025 | |
| Braintree Laboratories, INC. | $172.36 | 2021-2023 | Sutab |
| Celgene Corporation | $152.54 | 2023-2024 | Zeposia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151.40 | 2021-2024 | Dificid |
| Ardelyx, INC. | $146.13 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $128.11 | 2024-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $117.49 | 2023-2025 | Dupixent |
| Lucid Diagnostics INC. | $107.78 | 2023 | |
| Intercept Pharmaceuticals, INC. | $100.40 | 2022-2024 | Ocaliva |
| Daiichi Sankyo INC. | $84.45 | 2020-2025 | Injectafer |
| Celltrion USA INC. | $78.35 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $68.93 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $57.80 | 2024-2025 | Voquezna |
| Laborie Medical Technologies Corp. | $56.32 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Echosens North America, INC. | $50.58 | 2023-2024 | Fibroscan |
| Redhill Biopharma INC. | $49.80 | 2021 | |
| Exact Sciences Corporation | $37.89 | 2023 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $36.89 | 2020 | |
| Enterra Medical, INC. | $29.14 | 2022-2024 | |
| Evoke Pharma, INC. | $26.12 | 2025 | |
| Organon LLC | $24.81 | 2023 | Hadlima |
| Amgen INC. | $21.78 | 2025 | |
| Axonics, INC. | $16.19 | 2024 | Axonics |
| Medspira, LLC | $15.49 | 2022 | |
| Alfasigma USA, INC. | $14.74 | 2021 | |
| Boston Scientific Corporation | $10.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Erlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.